Parn as a biomarker and therapeutic target
AssigneeThe Regents of the University of Colorado, a body corporate
InventorsRoy R. Parker, Shukla Siddharth
Life of this patent
Estimating the term…
Abstract
Increased PARN as an indicator of a cancer involving loss or reduction in p53 function. PARN is also provided as a therapeutic target for treating a cancer involving loss or reduction in p53 function. Methods of treating a subject having a cancer involving loss or reduction in p53 function based on the level of PARN in a test sample obtained from the subject and administering an effective amount of a PARN inhibitor, alone or in conjunction with another chemotherapeutic agent, to the subject to treat the cancer.
Claims11
A method of treating a subject having a cancer, the method comprising:
- a) obtaining a test sample from the subject;
- b) assaying the test sample to determine the levels of one or more of the following:
- poly (A)-specific ribonuclease (PARN), and phosphorylated PARN, wherein the level of PARN is performed by Northern blot analysis, Western blot analysis, quantitative or semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR), ligase chain reaction (LCR), transcription-mediated amplification (TMA), strand displacement amplification (SDA), and nucleic acid sequence-based amplification (NASBA);
- c) producing an expression profile of the PARN from the test sample;
- d) compare the expression profile of c) to a control sample, wherein the control sample;
- and
- e) determining that the cancer is a chemotherapeutically-sensitive cancer where the levels of PARN in the test sample are significantly higher than the control resulting in a loss of function or activity of tumor protein-53 (p53);
- and
- f) treating the subject with a chemotherapeutic cancer therapy selected from:
- alemtuzumab, altretamine, aminoglutethimide, amsacrine, anastrozole, azacitidine, bleomycin, bicalutamide, busulfan, capecitabine, carboplatin, carmustine, celecoxib, chlorambucil, 2-chlorodeoxyadenosine, cisplatin, colchicine, cyclophosphamide, cytarabine, cytoxan, dacarbazine, dactinomycin, daunorubicin, docetaxel, doxorubicin, epirubicin, estramustine phosphate, etodolac, etoposide, exemestane, floxuridine, fludarabine, 5-fluorouracil, flutamide, formestane, gemcitabine, gentuzumab, goserelin, hexamethylmelamine, hydroxyurea, hypericin, ifosfamide, imatinib, interferon, irinotecan, letrozole, leuporelin, lomustine, mechlorethamine, melphalen, mercaptopurine, 6-mercaptopurine, methotrexate, mitomycin, mitotane, mitoxantrone, nilutamide, nocodazole, paclitaxel, pentostatin, procarbazine, raltitrexed, rituximab, rofecoxib, streptozocin, tamoxifen, temozolomidc, teniposide, 6-thioguanine, topotecan, toremofme, trastuzumab, vinblastine, vincristine, vindesine, and vinorelbine.
The method of claim XX100, wherein said step of assaying comprises detecting the amount of mRNA transcripts in the sample encoding a PARN protein according to SEQ ID NO's. 1-4.
The method of claim XX100, wherein said wherein said step of assaying comprises detecting the amount of PARN protein in the sample according to SEQ ID NO's. 1-4.
The method of claim XX100, wherein said cancer is selected from the group consisting of:
- acoustic neuroma, acute leukemia, acute lymphocytic leukemia, acute monocytic leukemia, acute myeloblastic leukemia, acute myelocytic leukemia, acute myelomonocytic leukemia, acute promyelocytic leukemia, acute erythroleukemia, adenocarcinoma, angiosarcoma, astrocytoma, basal cell carcinoma, bile duct carcinoma, bladder carcinoma, brain cancer, breast cancer, bronchogenic carcinoma, cervical cancer, chondrosarcoma, chordoma, choriocarcinoma, chronic leukemia, chronic lymphocytic leukemia, chronic myelocytic leukemia, colon cancer, colon carcinoma, craniopharyngioma, cystadenocarcinoma, embryonal carcinoma, enotheliosarcoma, ependymoma, epithelial carcinoma, Ewing's tumor, glioma, heavy chain disease, hemangioblastoma, hepatoma, Hodgkin's disease, large cell carcinoma, leiomyosarcoma, liposarcoma, lung cancer, lung carcinoma, lymphangioendotheliosarcoma, lymphangiosarcoma, macroglobulinemia, medullary carcinoma, medulloblastoma, melanoma, meningioma, mesothelioma, myxosarcoma, neuroblastoma, non-Hodgkin's disease, oligodendroglioma, osteogenic sarcoma, ovarian cancer, pancreatic cancer, papillary adenocarcinomas, papillary carcinoma, pinealoma, polycythemia vera, prostate cancer, rhabdomyosarcoma, renal cell carcinoma, retinoblastoma, schwannoma, sebaceous gland carcinoma, seminoma, small cell lung carcinoma, squamous cell carcinoma, sweat gland carcinoma, synovioma, testicular cancer, uterine cancer, Waldenstrom's fibrosarcoma, and Wilm's tumor.
A method of treating a subject having a cancer, the method comprising:
- a) obtaining a test sample from the subject;
- b) assaying the test sample to determine the levels of one or more of the following:
- poly (A)-specific ribonuclease (PARN), and phosphorylated poly (A)-specific ribonuclease (PARN), wherein the level of PARN is performed by Northern blot analysis, Western blot analysis, quantitative or semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR), ligase chain reaction (LCR), transcription-mediated amplification (TMA), strand displacement amplification (SDA), and nucleic acid sequence-based amplification (NASBA);
- c) producing an expression profile of the PARN from the test sample;
- d) compare the expression profile of c) to a control sample;
- e) determining that the cancer is a chemotherapeutically-resistant cancer where the levels of PARN in the test sample are significantly lower than the control sample;
- f) treating the subject with a non-chemotherapeutic cancer therapy selected from:
- radiotherapy, surgery, immunotherapy, kinase inhibition, monoclonal antibody therapy, or a combination thereof;
- ceasing chemotherapeutic treatments on the subject, or inhibiting the activity of expression of PARN.
The method of claim XX100, wherein said step of assaying comprises detecting the amount of mRNA transcripts in the sample encoding a PARN protein according to SEQ ID NO's. 1-4, or a functional fragment thereof.
The method of claim XX100, wherein said wherein said step of assaying comprises detecting the amount of PARN protein in the sample according to SEQ ID NO's. 1-4, or a functional fragment thereof.
The method of claim XX100, wherein said cancer is selected from the group consisting of:
- acoustic neuroma, acute leukemia, acute lymphocytic leukemia, acute monocytic leukemia, acute myeloblastic leukemia, acute myelocytic leukemia, acute myelomonocytic leukemia, acute promyelocytic leukemia, acute erythroleukemia, adenocarcinoma, angiosarcoma, astrocytoma, basal cell carcinoma, bile duct carcinoma, bladder carcinoma, brain cancer, breast cancer, bronchogenic carcinoma, cervical cancer, chondrosarcoma, chordoma, choriocarcinoma, chronic leukemia, chronic lymphocytic leukemia, chronic myelocytic leukemia, colon cancer, colon carcinoma, craniopharyngioma, cystadenocarcinoma, embryonal carcinoma, endotheliosarcoma, ependymoma, epithelial carcinoma, Ewing's tumor, glioma, heavy chain disease, hemangioblastoma, hepatoma, Hodgkin's disease, large cell carcinoma, leiomyosarcoma, liposarcoma, lung cancer, lung carcinoma, lymphangioendotheliosarcoma, lymphangiosarcoma, macroglobulinemia, medullary carcinoma, medulloblastoma, melanoma, meningioma, mesothelioma, myxosarcoma, neuroblastoma, non-Hodgkin's disease, oligodendroglioma, osteogenic sarcoma, ovarian cancer, pancreatic cancer, papillary adenocarcinomas, papillary carcinoma, pinealoma, polycythemia vera, prostate cancer, rhabdomyosarcoma, renal cell carcinoma, retinoblastoma, schwannoma, sebaceous gland carcinoma, seminoma, small cell lung carcinoma, squamous cell carcinoma, sweat gland carcinoma, synovioma, testicular cancer, uterine cancer, Waldenstrom's fibrosarcoma, and Wilm's tumor.
A kit for diagnosing a chemotherapy-resistant or chemotherapy-sensitive cancer in a patient comprising:
- one or more reagent(s) capable of measuring one or more feature(s) in a cancer cell(s) from said patient selected from the group consisting of:
- levels of cytoplasmic or nuclear PARN protein;
- levels of PARN protein or RNA;
- levels of phosphorylated PARN protein in the cytoplasm or nucleus;
- and, instructions for using these reagents to determine the presence of a chemotherapy-resistant or chemotherapy-sensitive cancer in said patient.
Dependencies are inferred from the claim text.